KCTD12 Activators

KCTD12 activators largely involve chemicals that can influence the signaling of GABAB and GABAA receptors. These receptors are central to the function of KCTD12, and therefore any alteration in their signaling can indirectly modulate KCTD12 activity. The chemicals include both agonists and antagonists of the GABAB and GABAA receptors. Agonists act by enhancing receptor signaling, while antagonists act by blocking the receptors.

Baclofen, GABA, and SKF 97541, for instance, are GABAB receptor agonists. They activate the receptor, which can indirectly enhance the function of KCTD12. Similarly, Zolpidem is a GABAA receptor agonist, and its activation of GABAA receptor can also indirectly modulate KCTD12 activity. On the other hand, CGP 55845, SGS742, Phaclofen, and CGP 54626 are GABAB receptor antagonists. By blocking the receptor, they can indirectly influence KCTD12 function. Similarly, L-655,708, Flumazenil, and Picrotoxin are GABAA receptor antagonists that can indirectly modulate KCTD12 activity by blocking GABAA receptor signaling.